These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24113758)

  • 1. [Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess].
    Soda T; Fukumoto R; Hayashi T; Oka D; Fujimoto N; Koide T
    Hinyokika Kiyo; 2013 Sep; 59(9):587-91. PubMed ID: 24113758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.
    Bantis A; Zissimopoulos A; Sountoulides P; Kalaitzis C; Giannakopoulos S; Deftereos S; Tsakaldimis G; Thomaidis V; Touloupidis S
    Tumori; 2011; 97(4):479-83. PubMed ID: 21989437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
    Mücke T; Deppe H; Hein J; Wolff KD; Mitchell DA; Kesting MR; Retz M; Gschwend JE; Thalgott M
    J Craniomaxillofac Surg; 2016 Oct; 44(10):1689-1693. PubMed ID: 27555374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Case of Bisphosphonate-Related Osteonecrosis of the Jaw with Difficulty in Treatment].
    Nakamura K; Fukumoto T; Fukui T; Sakatani T; Atsuta T; Kato T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2016 Jan; 62(1):39-44. PubMed ID: 26932335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
    BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonate-induced osteonecrosis of the jaw in a patient with metastatic breast cancer].
    Amrani Raissouni T; Moya Espinosa P; Ramos Moreno E; Martínez Del Valle Torres MD; Sanz Viedma S; Ortega Lozano SJ
    Rev Esp Med Nucl; 2011; 30(5):322-3. PubMed ID: 21440957
    [No Abstract]   [Full Text] [Related]  

  • 8. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Ristow M; Koerdt S; Schuster R; Otto S; Pautke C
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
    Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
    J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
    [No Abstract]   [Full Text] [Related]  

  • 10. Avascular osteonecrosis of the mandible following bisphosphonate therapy.
    Chandra PA; Chandra AB; Todd GK
    Am J Ther; 2009; 16(1):65-7. PubMed ID: 22573056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
    Wynn RL
    Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815
    [No Abstract]   [Full Text] [Related]  

  • 14. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Otto S; Pautke C
    J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
    Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
    Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.
    Wasserzug O; Kaffe I; Lazarovici TS; Weissman T; Yahalom R; Fliss DM; Yarom N
    Am J Rhinol Allergy; 2017 Jan; 31(1):36-39. PubMed ID: 28234151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.